Clinical Trials

  • Sequential Natalizumab–Alemtuzumab Therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS)
    ClinicalTrials.gov Identifier: NCT03135249
  • Cladribine Tablets after treatment with natalizumab (CLADRINA)
    ClinicalTrials.gov Identifier: NCT04178005
  • CLadribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous
    System BiomarKers in Multiple Sclerosis (CLOCK-MS)
    ClinicalTrials.gov Identifier: NCT03963375
  • Lipoic acid for Treatment of Progressive Multiple Sclerosis. (LAPMS)
    ClinicalTrials.gov Identifier: NCT03161028
  • Mitochondrial capacity boost in ALS (MICABO-ALS) trial.
    ClinicalTrials.gov Identifier: NCT04244630